AACR Poster Presentations
The posters presented at AACR by
Margetuximab is a novel, investigational anti-HER2 monoclonal antibody (mAb) with an Fc domain engineered to increase the molecule’s ability to engage certain Fc-gamma receptors of cells of the innate immune system to enhance killing of tumor cells. SOPHIA, a Phase 3 clinical trial of margetuximab in HER2-positive metastatic breast cancer patients, met the primary endpoint of prolongation of progression-free survival (PFS) in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy.
Preclinical data presented at AACR showed that margetuximab, while retaining the same Fc-independent tumor growth-inhibition activity as trastuzumab, exhibited more potent antibody-dependent cell-mediated cytotoxicity (ADCC) and induced greater activation and proliferation of NK cells in vitro compared to trastuzumab. In addition, the combination of margetuximab and pertuzumab mediated ADCC in vitro with greater potency than the combination of trastuzumab and pertuzumab.
- Abstract #1538: Margetuximab Mediates Greater Fc-dependent Anti-tumor Activities than Trastuzumab or Pertuzumab In Vitro
“In margetuximab, we have designed an Fc-enhanced antibody that has been shown in a Phase 3 trial to have a superior PFS outcome to that of trastuzumab, an analog antibody with a wild-type Fc domain,” said
MGA012 (INCMGA0012) is an investigational anti-PD-1 mAb exclusively licensed to
Data presented at AACR by
- Abstract #CT085: Pharmacodynamic Correlates in a Phase 1 Study of INCMGA00012, a PD-1 Antagonistic Monoclonal Antibody
- Abstract #LB-268: Assessment of Flat Dosing Strategy for INCMGA00012 in Patients with Advanced Tumors
IMGC936 is a novel, investigational antibody-drug conjugate (ADC) targeting ADAM9, a cell surface protein overexpressed in multiple solid tumor types. IMGC936 is being advanced under a co-development agreement with
- Abstract #1533: IMGC936, a First-in-Class ADAM9-targeting Antibody-Drug Conjugate, Demonstrates Promising Anti-tumor Activity
CD137-based TRIDENT™ Molecules
CD137 (4-1BB) signaling provides co-stimulation of CD8 or NK cells following antigen or FcγR engagement, respectively. However, efforts to leverage CD137 co-stimulation via agonistic mAbs have been thwarted by limited clinical efficacy or unacceptable toxicity. Bispecific targeting strategies linking CD137 activation to a tumor-targeting moiety provides an approach to localize CD137 activation to the tumor microenvironment. MacroGenics’ TRIDENT platform reflects the continuing evolution of the Company’s multi-specific antibody-based targeting expertise. Preclinical data presented at AACR demonstrate the potential for TRIDENT molecules with a 2:1 valency to maximize immune co-stimulatory activity through CD137 engagement that is dependent upon the presence of the target tumor antigen:
- Abstract #554: Tumor-antigen 5T4-dependent Activation of the CD137 Costimulatory Pathway by Bispecific 5T4 x CD137 TRIDENT™ molecules
- Abstract #1560: Selection of a Bispecific Trivalent HER2 x CD137 x CD137 TRIDENT™ Format Providing Optimal Tumor-anchored Immune Co-stimulation
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the
MacroGenics, Inc. Jim Karrels, Senior Vice President, CFO Anna Krassowska, Ph.D., Vice President, Investor Relations & Corporate Communications 1-301-251-5172, email@example.com MacDougall Biomedical Communications Karen Sharma, Senior Vice President 1-781-235-3060, firstname.lastname@example.org
Source: MacroGenics, Inc.